<DOC>
	<DOCNO>NCT02003014</DOCNO>
	<brief_summary>To investigate safety efficacy long-term treatment pioglitazone ( Actos tablet ) combination biguanides ( 12 month start pioglitazone tablet treatment ) patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Pioglitazone Tablets Special Drug Use Surveillance `` Combined Use Biguanides / Long-term Treatment ''</brief_title>
	<detailed_description>This special drug use surveillance observation period 12 month design investigate safety efficacy pioglitazone ( Actos ) routine clinical setting patient type 2 diabetes mellitus respond inadequately treatment biguanides addition diet therapy exercise therapy ( plan sample size , 1000 ) . The usual adult dosage 15 30 mg pioglitazone administer orally daily breakfast . Dose adjustment make accord gender , age , symptom upper limit 45 mg .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Patients type 2 diabetes mellitus respond inadequately treatment biguanides addition diet therapy exercise therapy 2 . Patients available HbA1c data within 1 month prior start Actos Tablets treatment 3 . Patients likely available 12month observation start Actos Tablets treatment 1 . Patients receive Actos Tablets within past 3 month . 2 . Patients start treatment biguanides Actos Tablets simultaneously 3 . Patients discontinue biguanides switch Actos Tablets treatment . 4 . Patients receive additional biguanides start Actos Tablets treatment 5 . Patients contraindication Actos Tablets treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>